Lupus & antiphospholipid syndrome
Belimumab outperforms placebo for attainment of modified Definition Of Remission In SLE (DORIS) remission and Lupus Low Disease Activity State (LLDAS) without the glucocorticoid component: a post hoc analysis of five phase III systemic lupus erythematosus (SLE) trials
Pooled result · Non-GC-DORIS attainmentResult — go to the resultRelative risk 1.44 95% CI 1.20–1.71Authors' conclusion
Belimumab was associated with higher attainment of DORIS remission and LLDAS excluding the GC component versus placebo; attainment rates were approximately twofold higher than those previously reported using the full definitions.
Study context
- Population
- Adults with SLE in five phase III trials (BLISS-76, BLISS-52, North East Asia, BLISS-SC, EMBRACE)5 trials
- Participants
- 1,869 vs 1,217
- Comparison
- Belimumab plus standard therapy vs placebo plus standard therapy
- Belimumabn = 1,869
- Placebon = 1,217reference
- Outcome
- Non-GC-DORIS and non-GC-LLDAS attainment (DORIS and LLDAS excluding the glucocorticoid (GC) component; based on SLEDAI-2K and PGA only)
- Follow-up
- Up to week 52
Methodological detailspooled data, placebo-controlled
- Pooled data
- Placebo-controlled
Pooled result
Non-GC-DORIS attainment
Relative risk
1.44
95% CI 1.20–1.71
P < 0.001
By group
Belimumabvs Placebo
RR 1.44 (95% CI 1.20–1.71); P < 0.001
As reported in the abstract
Further pooled results
| Outcome | Belimumab | Placebo | RR (95% CI) | P value | |
|---|---|---|---|---|---|
| Non-GC-LLDAS attainment · up to week 52 | 32% | 21% | 1.50 (1.32–1.71) | P < 0.001 | |
| 0.512Relative risk (log scale) |
Patient subgroups · up to week 52
- Similar results across most analysed subgroups; differences generally greater in high vs low disease activity subgroups; Asian and White subgroups had significantly higher attainment with belimumab vs placebo
Original publication
Belimumab outperforms placebo for attainment of modified DORIS remission and LLDAS without the glucocorticoid component: a post hoc analysis of five phase III SLE trials. RMD Open. Published 3 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →